AstraZeneca Offloads Non-Core Products to Raise Money for New Drugs -- Market Talk
November 13 2018 - 4:40AM
Dow Jones News
0910 GMT - AstraZeneca's partial divestment of anti-infective
treatment Synagis to Sobi follows a pattern of deals that offload
"non-core" products to raise money for its pipeline of new drugs.
Synagis, a treatment that prevents respiratory tract infections in
infants, falls outside of AstraZeneca's focus areas of cancer,
diabetes, cardiovascular medicine, and chronic respiratory
conditions like asthma. Astra has sold off a string of drugs that
do not fit into these areas in recent years, and plowed the
proceeds into research and marketing for those that do. Astra
shares are up 0.9% to GBP63.09 Tuesday morning. (
denise.roland@wsj.com ; @deniseroland) -0---Denise RolandREPORTER
O: +44 (0)
(END) Dow Jones Newswires
November 13, 2018 04:25 ET (09:25 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024
